OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chedid on Understanding Treatment Efficacy in Follicular Lymphoma

September 29th 2022

Solly Chedid, MD, discusses the elements of effective therapy in follicular lymphoma.

Dr. Patel on Factors to Consider When Treating Relapsed/Refractory Follicular Lymphoma

September 29th 2022

Krish Patel, MD, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.

Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid Tumors

September 28th 2022

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

Dr. Schmid on the Use of Preoperative Radiation Therapy in Urothelial Carcinoma

September 28th 2022

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Dr. Ansell on the LOTIS-2 Trial of Loncastuximab Tesirine in R/R DLBCL

September 27th 2022

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Paul on the Management of CRS and ICANS After CAR T-cell Therapy in Cancer Care

September 27th 2022

Barry Paul, MD, discusses the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome following CAR T-cell therapy in cancer care.

Dr. Gerds on the VERIFY Trial Examining Rusfertide in Polycythemia Vera

September 27th 2022

Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.

Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLC

September 27th 2022

Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.

Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

September 26th 2022

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Dr. Barata on the Evolving Treatment Landscape in Urothelial Cancer

September 26th 2022

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Dr. Verstovsek on the Potential Role of Rusfertide in Polycythemia Vera

September 26th 2022

Srdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.

Dr. Girard on Examining the Real-World Effectiveness of Lurbinectedin in SCLC

September 26th 2022

Nicolas Girard, MD, PhD, discusses the investigation of lurbinectedin in small cell lung cancer.

Dr. Mascarenhas on the Investigation of Pelabresib in Myelofibrosis

September 23rd 2022

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

Dr. Aragon-Ching on the Evolving Standard of Care with JAVELIN Bladder 100 in Urothelial Carcinoma

September 23rd 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Dr. Orellana-Noia on the Patient Population of the POLARIX Trial in DLBCL

September 23rd 2022

Victor M. Orellana-Noia, MD, discusses the patient population of the phase 3 POLARIX trial in diffuse large B-cell lymphoma.

Dr. Moon on the Future of Care in Prostate Cancer

September 21st 2022

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Dr. Aragon-Ching on the Implications of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

September 21st 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Dr. Matasar on the Unmet Needs of Immunotherapy for DLBCL

September 21st 2022

Matthew J. Matasar, MD, discusses the unmet needs remaining in diffuse large B-cell lymphoma.

Dr. Llanos on Genetic Disparities in Cancer Care

September 21st 2022

Adana A.M. Llanos, PhD, MPH, discusses disparities in genetic research in cancer care.

Dr. Goetz on the ELAINE-1 Trial of Lasofoxifene in ESR1-Mutated, ER+/HER2- Breast Cancer

September 19th 2022

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.